Authors
Katia De Marco, Marialaura Latrofa, Giovanna Forte, Martina Lepore Signorile, Elisabetta Di Nicola, Paola Sanese, Candida Fasano, Vittoria Disciglio, Erica Candela, Sergio Coletta, Valentina Grossi, Cristiano Simone
Published in
Journal of experimental & clinical cancer research : CR. Volume 45. Issue 1. Sep 12, 2026. Epub Sep 12, 2026.
Abstract
SMYD3 is a histone methyltransferase implicated in cancer progression and is overexpressed in several malignancies, including gastric cancer (GC). Building on previous evidence linking SMYD3 to DNA damage repair, we investigated the molecular mechanisms through which SMYD3 regulates double-strand break (DSB) repair in GC and evaluated its therapeutic potential.
In silico and in vitro analyses were performed to investigate the interactions between SMYD3 and key homologous recombination (HR) proteins, and to evaluate the ATM-mediated phosphorylation of SMYD3. Functional assays assessed the impact of pharmacological SMYD3 inhibition on HR and non-homologous end joining (NHEJ) repair pathways.
Mechanistically, SMYD3 interacted with key HR factors and facilitated chromatin remodeling at damaged sites. ATM phosphorylated SMYD3 at threonine 22, a modification required for HR complex assembly and validated in GC patient samples following neoadjuvant chemotherapy. Inhibition of SMYD3 abolished HR and partially impaired NHEJ. Combined inhibition of SMYD3 and PARP induced synthetic lethality in GC cells, spheroids, and patient-derived organoids, and overcame resistance to olaparib.
These findings reveal the ATM-dependent molecular mechanism by which SMYD3 regulates DNA DSB repair, further supporting SMYD3 as a promising therapeutic target for precision oncology strategies in GC.
PMID:
42778940
Bibliographic data and abstract were imported from PubMed on 24 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 21
- Comments 0